What We're Reading: Page 284
Industry reads hand-picked by our editors
Mar 08, 2018
-
Bloomberg BNA
Pharma class is in session more and more
-
Reuters
Sanofi may seek U.S. approval for Dengvaxia despite Philippines outrage
-
CNN
Cancer treatment guidelines questioned in new study
-
Xconomy
Prevail gets $75M for Parkinson’s gene therapy, bolstering NY biotech
-
Associated Press
FDA did not issue new statement on vaccines and autism
Mar 07, 2018
-
Fortune
How stale is innovation in drug discovery? Think: 5-year-old yogurt.
-
Medical Marketing & Media
Xbox for Docs: Pharma backs AR games for use in physician learning
-
Boston Business Journal
State's biotech IPO class of 2017 gets mixed reviews from investors
Mar 06, 2018
-
The Boston Globe
A path forward for experimental drug treatments
-
Bloomberg Gadfly
Dermira reminds investors what binary means in biotech
-
Associated Press
FDA chief wants more mail inspectors to stem opioid influx
Mar 05, 2018
-
Reuters
China's Tasly to list biotech arm in $1 billion Hong Kong IPO: sources
-
Chemical & Engineering News
Why can’t the drug industry solve its gender diversity problem?
-
Regulatory Focus
May on Brexit: UK should remain part of EMA
-
PBS
Gene therapy was a boy’s last chance to stop leukemia. And it worked.
Mar 02, 2018
-
Harvard Business Review
Will personalized medicine mean higher costs for consumers?
-
Healthcare Dive
4 questions on Uber's new healthcare platform
-
The Washington Post
How proton therapy attacks cancer
-
CNBC
Activist Alex Denner to gain board control at Medicines Company
Mar 01, 2018
Feb 28, 2018
-
CNBC
Walgreens and AmerisourceBergen deal talks have cooled as takeover looks unlikely
-
Financial Times
Henri Termeer’s legacy is a vibrant biotech sector
-
Reuters
Why Oppenheimer Global fund is focusing on biotech as rates rise
-
Associated Press
Trump administration weighs mental health coverage option
Previous
